Extract from M&A Insights

M&A Insights is our fully-fledged M&A platform for teams operating in the Nordics and DACH countries, enabling clients to identify and qualify opportunities well in advance of any structured process.
Karo Pharma acquires a 10 product portfolio from Leo Pharma
March 1, 2018

Leo Pharma has divested a 10 product portfolio to Swedish-based Karo Pharma. It is fully aligned with Leo Pharma 2025 strategy to focus on new medical solutions and divest current. The deal value amounted to EUR 260 m.

ⓘ This story was originally featured in our daily M&A Newsletter - a part of M&A Insights.
Our insights have been covered by: